Literature DB >> 17877481

Recent advances in the diagnosis of hepatocellular carcinoma.

Fabio Piscaglia1, Luigi Bolondi.   

Abstract

In the last decade, new imaging techniques have become available, offering the possibility of investigating contrast perfusion of liver nodules in cirrhosis. It is now accepted that a non-invasive diagnosis of hepatocellular carcinoma (HCC) can be established based on the vascular pattern, obtained with pure blood pool contrast agents. The diagnostic pattern includes: hypervascularity in the arterial phase (15-35 s after contrast injection), consisting in a contrast signal in the nodule greater than in the surrounding parenchyma, followed by contrast wash out, which leads the nodule to show the same, or, more specifically, a lower contrast signal, than the surrounding parenchyma in the portal and late phases (>40 s after injection). Such a pattern can be obtained not only by computed tomography or magnetic resonance imaging, but also by contrast-enhanced ultrasonography, most simply with real-time low mechanical index harmonic imaging ultrasound equipment with second-generation ultrasound contrast agents. The risk of false-positive diagnosis of malignancy isnearly abolished when the functional vascular pattern is not the only feature, but is superimposed on a nodule visible also without contrast. One single contrast imaging technique may suffice to make a diagnosis of HCC if the nodule is >1 cm in diameter and has developed during a surveillance program. Other types of contrast agents, such as those taken up by the reticular-endothelial system cells, may offer additional diagnostic clues, but definitive evidence of their efficacy is still to be produced. In conclusion, contrast-enhanced imaging techniques now offer the possibility of a non-invasive diagnosis of HCC in a large number of cases, reducing the need of invasive investigations, such as ultrasound-guided biopsy or angiography.

Entities:  

Year:  2007        PMID: 17877481     DOI: 10.1111/j.1872-034X.2007.00183.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  6 in total

1.  Needle track seeding following percutaneous procedures for hepatocellular carcinoma.

Authors:  Giuseppe Cabibbo; Antonio Craxì
Journal:  World J Hepatol       Date:  2009-10-31

2.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

3.  The potential use of 2-[¹⁸F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma.

Authors:  Michael Sørensen; Kim Frisch; Dirk Bender; Susanne Keiding
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

4.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

5.  Survival of patients with primary liver cancer in central and northern Denmark, 1998-2009.

Authors:  Jonathan Montomoli; Rune Erichsen; Mette Nørgaard; Morten Høyer; Jesper Bach Hansen; Jacob Bonde Jacobsen
Journal:  Clin Epidemiol       Date:  2011-07-21       Impact factor: 4.790

Review 6.  Progress in stem cell-derived technologies for hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  Stem Cells Cloning       Date:  2010-05-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.